Additional file 1: Figure S1. of Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients

Gating strategies of monocytic MDSC and granulocytic MDSC in the peripheral blood. Gating strategies of flow cytometry analysis of monocytic MDSC (CD11b+CD14+HLA-DRlo/-) and granulocytic MDSC (Lin−CD11b+CD15+) from HNSCC patients were plotted in A and B, respectively. Figure S2. Similar baseline expression of CD16 on circulating monocytic MDSC in 08–013 responsers and non-responders. Summary data of frequency of CD16+ cells and MFI of CD16 in CD14+HLA-DRlo/- cells in responders (n = 10) and non-responders (n = 19) of UPCI 08–013 trial pre-cetuximab treatment. Statistical significance was determined by Mann Whitney test. (PPTX 553 kb